Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.15 USD | -2.06% | -0.88% | -3.00% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 61% by 2026.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company benefits from high valuations in earnings multiples.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.00% | 1.83B | D+ | ||
-14.25% | 85.02B | B- | ||
+14.46% | 82.37B | C+ | ||
+9.37% | 29.29B | C+ | ||
-11.40% | 17.21B | B | ||
-0.36% | 16.7B | A- | ||
+0.22% | 15.5B | A- | ||
+4.32% | 12.15B | A- | ||
-2.34% | 12.13B | A- | ||
+32.69% | 12.12B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ASTH Stock
- Ratings Astrana Health, Inc.